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Highlights 
• 17 EBMT centers participated to a questionnaire on MSC manufacturing  
• 88% of centers manufacture MSC from bone marrow, only 2 centers from umbilical 
cord  
• Human platelet lysate has replaced bovine serum as culture medium supplement 
• Release criteria extensively differ amongst centers 
• The results highlight the need to harmonize MSC manufacturing 
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Abstract 
Background. The immunosuppressive properties of mesenchymal stromal cells (MSC) have been 
successfully tested to control clinical severe graft-versus host disease (GvHD) and improve 
survival. However, clinical studies have not yet provided conclusive evidence of their efficacy 
largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is 
also a major contributing factor, as manufacturing of therapeutic MSC is performed according to 
different protocols amongst different centers. Understanding the variability of the manufacturing 
protocol would allow a better comparison of the results obtained in the clinical setting amongst 
different centers. In order to acquire information on MSC manufacturing we have sent a 
questionnaire to the European Group for Blood and Marrow Transplantation (EBMT) centers 
registered as producing MSC.   
Methods. Data from 17 centers were obtained and analyzed by means of a two-phase questionnaire 
specifically focused on product manufacturing. Gathered information included MSC tissue sources, 
MSC donor matching, medium additives for ex-vivo expansion, data on MSC product specification 
for clinical release. 
Results. The majority of centers manufactured MSC from bone marrow (88%), whilst only two 
centers produced MSC from umbilical cord blood or cord tissue. One of the major changes in the 
manufacturing process has been the replacement of fetal bovine serum with human platelet lysate as 
medium supplement. 59% of centers used only third-party MSC, whilst only one center 
manufactured exclusively autologous MSC. The large majority (71%) of these facilities 
administered MSC exclusively from frozen batches. Aside from variations in the culture method, 
we found large heterogeneity also regarding product specification, particularly in the markers used 
for phenotypical characterization and their threshold of expression, use of potency assays to test 
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MSC functionality and karyotyping.  
Discussion. The initial data collected from this survey highlight the variability in MSC 
manufacturing as clinical products and the need for harmonization. Until more informative potency 
assays become available, a more homogeneous approach to cell production may at least reduce 
variability in clinical trials and improve interpretation of results. 
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Introduction 
The preparation of mesenchymal stromal cells (MSC) in experimental and clinical studies consists 
of a highly heterogeneous population that can be isolated from virtually all human tissues and easily 
expanded ex vivo. A proportion of cultured MSC, like activated fibroblasts, exhibit progenitor 
activity because they can differentiate in vitro into the three mesenchymal lineages
1
, but the 
significance of these in vitro assays to document multipotency can be misleading and has recently 
been questioned
2
. However, in vivo studies have better characterized subpopulations with genuine 
stemness and the specific ability to form components of the osteogenic
3
 and vascular
4
 stem cell 
niche. 
Also similarly to activated fibroblasts
5
, MSC are endowed with unique immunomodulatory and 
anti-inflammatory activities on adaptive
6
 and innate immune responses
7
. By reprogramming the 
inflammatory microenvironment
8
, MSC prime tissue repair, thus making them a therapeutic tool not 
only to control immune-mediated ailments but also in the context of regenerative medicine
9–11
. 
Therefore, it is not surprising that MSC therapeutics have met a huge interest in hematopoietic stem 
cell transplantation (HSCT) whereby they have been exploited to treat challenging conditions such 
as impaired HSC engraftment
12–14
 and steroid-resistant acute graft-versus-host disease (aGvHD)
15–
18
.  
The most employed and convincing clinical application of MSC in the setting of allogeneic HSCT 
remains the treatment of resistant aGvHD. The first report on a pediatric patient
19
 paved the way to 
several more controlled studies or compassionate use experiences demonstrating safety and 
encouraging efficacy in a large portion of patients which translated into an increased survival in 
those showing a complete response
15–18,20,21
. However, no randomized clinical trial has formally 
confirmed efficacy with the only one completed, performed with an industrial MSC product 
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(NCT00366145), that failed to reach the primary endpoint. An academic, EU-funded multicenter 
phase III study is ongoing in Europe and will hopefully contribute to clarify the impact of MSC in 
GvHD. Furthermore, highly successful phase III studies are being finalized by commercial 
companies (NCT02336230). 
These clinical studies are limited not only by the intrinsic heterogeneity of GvHD patients, but also 
by the variability in MSC preparations. According to European Regulation, MSC are classified as 
Advanced Therapy Medicinal Product (ATMP; European Regulation EC No. 1394/2007, and 
complying with regulation 2004/23/EC and 2002/98/EC) and, therefore, require specific regulatory 
framework for production under Good Manufacturing Practice (GMP) conditions, as well as criteria 
for product specification and release for clinical use
22
. Different tissue sources, expansion protocols 
and product definitions are employed across European centers, thus posing the question of whether 
the cell product is sufficiently similar across the manufacturing units and whether results can be 
reasonably compared even within the same study. Moreover, the yet incomplete definition of MSC 
has a substantial impact on release criteria and potency assays. Mechanism-based markers for 
potency capable of predicting clinical efficacy have only recently been proposed
23
. 
All these considerations and the large use of MSC for GvHD across Europe strongly argue for the 
need of harmonization and standardization of the processes involved in MSC manufacturing and 
their release criteria. To this aim, the Cellular Therapy & Immunobiology Working Party of the 
European Group for Blood & Marrow Transplantation (EBMT) has conducted a survey to collect 
information on MSC manufacturing and product specification in approved EBMT centers registered 
as producing MSC.  
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Methods 
The data reported were collected from 17 EBMT centers using a two-phase questionnaire dedicated 
to several aspects of the MSC manufacturing process.  The criterion used to select the participating 
centers was the participation of the center to the European Group of Blood and Marrow 
Transplantation (EBMT). The response rate was 100%, as all contacted centers replied to the first 
questionnaire. Centers which participated in the survey were located in Austria (Salzburg), Belgium 
(Leuven, Liege), Germany (Dresden, Frankfurt, Hannover), Israel (Tel-Ashomer), Italy (Bergamo, 
Milano, Monza, Pavia), Lithuania (Vilnius), the Netherlands (Leiden, Utrecht), Spain (Salamanca), 
Sweden (Stockholm) and the United Kingdom (London). They all hosted an approved facility for 
clinical grade MSC manufacturing. The indication for MSC administration was treatment of 
steroid-resistant aGvHD developed after allogeneic HSCT or donor lymphocyte infusion.  
Gathered information in the first questionnaire included tissue source (bone marrow, BM, cord 
blood or cord tissue, others), patient-donor matching (third-party and/or autologous MSC), medium 
supplements for in vitro expansion (fetal bovine serum, FBS; human platelet lysate, hPL; antibiotics 
or anti-fungal agents), use of fresh or frozen MSC products. Data on MSC product specification for 
clinical release covered expression of positive (CD90, CD105, CD73) and negative (CD45, CD31, 
CD3, CD19) markers by flow-cytometry and their threshold for clinical use. Safety was addressed 
by asking practice on karyotypic analysis, sterility, mycoplasma and endotoxin testing. Finally, 
centers were asked whether they performed any potency assay, including differentiation and 
immunosuppressive activity.  
 
The majority (71%) of centers participating in the first phase questionnaire agreed to provide data 
also in the second questionnaire, which included more specific questions on technical details related 
to the manufacturing process. This comprised information on mononuclear cell (MNC) and MSC 
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seeding density, use of flasks and/or factories or different expansion devices (such as bioreactors), 
cryopreservants employed for MSC freezing, and shelf life of the product. In addition, data on the 
number of in vitro MSC passages and the use of pooled cell products were collected. The two 
questionnaires are included as Supplementary Material. 
 
Data were collected in 2017 and included all MSC preparations generated from the date on which 
the centers received approval to produce clinical grade MSC. 
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Results 
In total, more than 1500 MSC treatments 
have been performed in the participating 
facilities in over a thousand of patients. 
The majority (88%) of centers 
manufactured MSC from BM as tissue 
source (Ficoll or whole BM), whereas 
only two centers produced MSC from 
umbilical cord blood or cord tissue (Figure 
1A). One of the major changes we 
observed in the manufacturing process has 
been the replacement of FBS with hPL as 
a medium supplement. 77% of centers 
currently use hPL, either commercially 
available or from pools of expired platelets 
obtained from the blood bank (Figure 1B). 
Further information about the specific 
composition of the isolation and expansion 
culturing media was collected through the answers to the second part of the questionnaire. 
Analyzing the available data from 12 centers, we found that 75% of the centers employing hPL 
used a concentration equal to 5% in both isolation and expansion media, while the remaining 
employed 10%. Only one center used 5% hPL for isolation medium and 10% hPL for expansion 
medium.  None of the centers used any growth factor for MSC manufacture. In 38% of the centers, 
Figure 1: Clinical MSC production in 17 GMP facilities in 
EBMT centers. Distribution charts expressing percentage of 
centers. A. Percentage of centers producing MSC from 
umbilical cord blood or cord tissue, or from bone marrow 
(BM), either using Ficoll method or adherence from whole 
BM. B. Percentage of centers using fetal bovine serum 
(FBS), or human platelet lysate (hPL) from commercially 
available manufacturers or from pooled expired platelets 
obtained from blood bank. C. Distribution of centers using 
allogeneic or autologous MSC. D. Percentage of centers 
delivering fresh or frozen MSC. 
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antibiotics were added to the MSC expansion medium (i.e. penicillin/streptomycin 1%), whereas in 
none of them anti-fungal agents were used in culture. 59% of centers prepared only third-party 
allogeneic MSC, whilst one center manufactured only patient-derived autologous MSC (Figure 1C). 
For all centers, donor eligibility requirements and donor age for allogeneic products were in line 
with Directive 2004/23/EC and Commission Directive 2006/17/EC. 71% of facilities administered 
MSC exclusively from frozen batches, whereas the remaining infused both fresh and frozen 
products (Figure 1D).  
Apart from variations in the culture method, we 
observed a large heterogeneity in product specification. 
Phenotypical characterization represented a 
fundamental release criterion for all centers, and all 
surveyed facilities conducted analysis for the 
expression of CD73, CD90 and CD105, and CD45 
through flow-cytometry. However, the threshold of 
marker expression that is accepted to be clinically 
graded was highly variable, with for example CD45 
expression varying between 1 and 20% (Figure 2A). 
Similarly, the threshold of positive marker expression 
varied from 70% to a very stringent 95%, the latter 
being employed by nearly half (44%) of the centers 
(Figure 2B). Furthermore, the addition of other 
markers to the standard panel was unsystematic, with 
a high variability in the release threshold levels and in 
Figure 2: Distribution charts on product 
specification for phenotype on clinical MSC. A. 
Distribution chart on the percentage of centers 
using different acceptance criteria for CD45 
expression. B. Distribution chart on the 
percentage of centers using different acceptance 
criteria for expression of markers CD73, CD90 
and CD105. C. Distribution graph on the 
percentage of centers using other markers 
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the type of markers analyzed. Most centers added CD19, CD34, CD14, HLA-DR and CD3 
negativity to the panel, while fewer centers checked expression of CD166, CD31 and CD44 (Figure 
2C).  
Alongside product specification, whilst all centers met the criteria of releasing sterile and 
mycoplasma-free product, not all of them (71%) evaluated the presence of endotoxin in the final 
formulation (Figure 3A). However, none of the centers ever had an out of specification result for 
sterility or endotoxin positivity, apart from one center that experienced incidental mycoplasma 
positivity in a product.  
When dealing with infusion of allogeneic BM MSC, only 31% of the centers responding to the 
second questionnaire produced pooled MSC products derived from different donors, generally 
obtained from two to three subjects. Noteworthy, only one center employed MSC products 
generated from pooled MNC of multiple BM donors
24
. All the facilities used passage two or 
passage three as limit of in vitro passage after which cells were not being released as clinical 
products. However, only one out of the twelve centers participating to the second phase 
questionnaire routinely calculated population doubling to assess MSC expansion before release. 
The level of seeding densities for MSC isolation from MNC and for MSC expansion did not show 
any overlay at all amongst centers, with single facilities having identified different concentrations of 
cells to be plated for the manufacturing process. The majority of centers continued to perform MSC 
expansion in cell culture flasks or cell factories, while only one facility was developing a 
bioreactor-based expansion system. The cryopreservation medium was based on dimethyl 
sulphoxide (DMSO) which was employed at 10% concentration in all centers except for one which 
adopted 5% concentration. The majority of centers measured post-thawing viability by Trypan Blue 
staining, with only three centers adopting the method of staining with 7-Aminoactinomycin D (7-
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AAD) or Annexin V and Propidium Iodide 
(PI) followed by flow cytometry of the 
stained sample. The shelf life for MSC 
before administration displayed a vast 
variability ranging from 8 months to 23 
years with one case in which no time limit 
was defined. Administration of the cells 
was performed intravenously or intra-
arterially. Before infusion, cells were 
diluted with saline solution, human 
albumin solution or directly administered in 
their cryopreservant.  
The majority of centers (71%) performed 
karyotyping which was evaluated by means 
of G-banding and by analyzing a minimum 
number of 20 metaphases (Figure 3B). 23% 
of the centers determined the differentiation ability of MSC into adipocyte and osteoblasts, and only 
three facilities tested also chondrocytic differentiation (Figure 3C). 29% percent of the centers 
performed a potency assay to validate MSC immunosuppressive activity and employed it as a 
release criterion (Figure 3D). This test varied amongst centers. Whilst one center analyzed the 
immunosuppressive activity of MSC against phytohemagglutinin-activated T cells, another center 
did so using anti-CD3/CD28 antibody-stimulation and two facilities tested MSC 
immunosuppression on a mixed lymphocyte reaction. Moreover, these more complex assays were 
not always performed together, as only two centers tested both immunosuppression and 
Figure 3: Distribution chart on release criteria for clinical 
MSC. A. Percentage of centers using sterility and absence of 
mycoplasma species or sterility, absence of mycoplasma 
species and endotoxin levels as release criteria for clinical 
MSC. B. Percentage of centers performing analysis of 
karyotype. C. Percentage of centers analyzing differentiation 
ability of MSC: tri-lineage differentiation into adipocytes, 
osteoblasts and chondrocytes; two-lineage differentiation into 
adipocytes and osteoblasts; no differentiation assay carried 
out. D. Percentage of centers determining immunosuppressive 
activity of MSC (potency assay). 
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karyotyping, one center analyzed differentiation capacity and karyotype and one center examined 
differentiation alongside immunosuppressive activity. 
Discussion 
The immunosuppressive properties of MSC have been widely exploited in the clinical setting to 
control aGvHD resistant to conventional treatments. Despite the encouraging experience and the 
positive impact on the overall survival, there is still no formal proof of efficacy and the factors 
predictive of clinical responses have not yet been identified. What certainly complicates the 
interpretation of the results is the potential heterogeneity of MSC preparations and the absence of 
any mechanistic potency assay. Using the information from 17 EBMT-affiliated transplant centers 
registered to manufacture MSC, our survey has effectively documented a high variability in culture 
methods, and, even more importantly, in the list of release criteria for the clinical product.  
Despite a decline in its use as source of HSC for transplantation, BM remains the main MSC 
source. Certainly, a significant change in the manufacturing process has been the substitution, in the 
vast majority of facilities, of an animal protein-based additive (FBS) with hPL as a culture 
supplement
25
. Another common finding is the administration of third-party MSC products that have 
been stored in frozen batches. This has been made indispensable in order to allow acquisition of 
data on quality release tests. At the same time, it meets the important need of having an off-the-
shelf product promptly available for the treatment of patients affected by severe GvHD. Amongst 
the implementation of the safety measures we have observed that, although there is no evidence that 
infused MSC engraft irrespective of whether they are obtained from the patient or a third-party 
donor, the majority of centers regularly performs MSC karyotyping. Most of the centers never had 
an anomalous karyotyping result, however this might be due to the sensitivity of the sampling and 
of the test. Considering the practically inexistent risk of malignant transformation
26,27
, this labor-
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intensive procedure should be reviewed.  
Our survey also highlights the vast heterogeneity in product specification. This includes the 
phenotypic markers as well as the functional assays to test MSC potency before their clinical use. 
These many discrepancies are clearly the results of an inaccurate scientific definition of the MSC 
product and in particular the confusion between progenitor and anti-inflammatory activities that do 
not necessarily overlap. Many of the current release criteria should be revised as they are not 
entirely substantiated by scientific evidence or have been defined in an era in which many of the 
aspects of MSC biology had not yet been identified. Furthermore, the limited knowledge of their 
mode of action has certainly hindered the development of informative potency assays by which to 
select the most efficacious cell batch. It was only very recently that new insights into the 
immunosuppressive activity of MSC
23
 have suggested not only to investigate the cell preparation 
but also the cell recipient. 
In conclusion, this initial report highlights the variability present in MSC manufacturing and release 
criteria across European EBMT centers. Such variability may impact on MSC therapeutic activity 
and further complicate the already difficult interpretation of clinical results. Although release 
criteria should adapt to new scientific findings rather than opinionated consensus statements, 
manufacturing a single homogenous therapeutic reagent would at least eliminate one variable and 
allow us to concentrate on the more complex nature of MSC recipients. 
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